BRPI0716143A2 - Uso de tenecteplase para tratar derrame isquêmico agudo - Google Patents
Uso de tenecteplase para tratar derrame isquêmico agudo Download PDFInfo
- Publication number
- BRPI0716143A2 BRPI0716143A2 BRPI0716143-3A BRPI0716143A BRPI0716143A2 BR PI0716143 A2 BRPI0716143 A2 BR PI0716143A2 BR PI0716143 A BRPI0716143 A BR PI0716143A BR PI0716143 A2 BRPI0716143 A2 BR PI0716143A2
- Authority
- BR
- Brazil
- Prior art keywords
- approximately
- tenecteplase
- bolus
- dose
- minutes
- Prior art date
Links
- 108010039185 Tenecteplase Proteins 0.000 title claims description 147
- 229960000216 tenecteplase Drugs 0.000 title claims description 112
- 230000001154 acute effect Effects 0.000 title description 9
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 66
- 239000003814 drug Substances 0.000 claims description 51
- 238000001802 infusion Methods 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 34
- 239000003527 fibrinolytic agent Substances 0.000 claims description 33
- 229960000103 thrombolytic agent Drugs 0.000 claims description 30
- 238000001990 intravenous administration Methods 0.000 claims description 15
- 239000005557 antagonist Substances 0.000 claims description 13
- 239000004090 neuroprotective agent Substances 0.000 claims description 12
- 102000003886 Glycoproteins Human genes 0.000 claims description 10
- 108090000288 Glycoproteins Proteins 0.000 claims description 10
- 241000282412 Homo Species 0.000 claims description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 109
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 109
- 229960003318 alteplase Drugs 0.000 description 68
- 208000006011 Stroke Diseases 0.000 description 61
- 229940113038 tnkase Drugs 0.000 description 36
- 229960000187 tissue plasminogen activator Drugs 0.000 description 33
- 230000002537 thrombolytic effect Effects 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 16
- 206010000891 acute myocardial infarction Diseases 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 206010061216 Infarction Diseases 0.000 description 14
- 230000007574 infarction Effects 0.000 description 14
- 208000007536 Thrombosis Diseases 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 208000034158 bleeding Diseases 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000003146 anticoagulant agent Substances 0.000 description 10
- 238000004088 simulation Methods 0.000 description 10
- 102100025390 Integrin beta-2 Human genes 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 229940099983 activase Drugs 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 208000005189 Embolism Diseases 0.000 description 7
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 208000032109 Transient ischaemic attack Diseases 0.000 description 7
- 210000001627 cerebral artery Anatomy 0.000 description 7
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 7
- 201000010875 transient cerebral ischemia Diseases 0.000 description 7
- 206010014498 Embolic stroke Diseases 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 6
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001361 intraarterial administration Methods 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 229960005202 streptokinase Drugs 0.000 description 6
- 229960005356 urokinase Drugs 0.000 description 6
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 5
- 206010063045 Effusion Diseases 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000007971 neurological deficit Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108010051412 reteplase Proteins 0.000 description 5
- 229960002917 reteplase Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000288900 Desmodus rotundus Species 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 4
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 4
- 108010023197 Streptokinase Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- XLZOVRYBVCMCGL-BPNVQINPSA-L disodium;4-[(z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate Chemical compound [Na+].[Na+].CC(C)(C)[N+](\[O-])=C\C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XLZOVRYBVCMCGL-BPNVQINPSA-L 0.000 description 4
- 230000003073 embolic effect Effects 0.000 description 4
- 229960000610 enoxaparin Drugs 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 229940127126 plasminogen activator Drugs 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- -1 saroplase Proteins 0.000 description 4
- 239000003998 snake venom Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 108010001779 Ancrod Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010056764 Eptifibatide Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 3
- 102000001938 Plasminogen Activators Human genes 0.000 description 3
- 108010001014 Plasminogen Activators Proteins 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960004233 ancrod Drugs 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000010102 embolization Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 108010051044 lanoteplase Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108010073863 saruplase Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 2
- 108010058207 Anistreplase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 108010090109 Fibrolase Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 2
- 206010058558 Hypoperfusion Diseases 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000983 anistreplase Drugs 0.000 description 2
- 230000001030 anti-leukocytic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960004468 eptifibatide Drugs 0.000 description 2
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229950010645 lanoteplase Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108010068982 microplasmin Proteins 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 108010075698 monteplase Proteins 0.000 description 2
- 229950005805 monteplase Drugs 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000002345 thrombinlike Effects 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- VYDDCJKXVNKSGD-UHFFFAOYSA-N 3-azaniumyl-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoate Chemical compound CC=1ONC(=O)C=1C(N)CC(O)=O VYDDCJKXVNKSGD-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 206010068737 Facial asymmetry Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 101100019412 Homo sapiens ITGB2 gene Proteins 0.000 description 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010022840 Intraventricular haemorrhage Diseases 0.000 description 1
- 108010031891 KHRR 296-299 AAAA T103N Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- LRUUNMYPIBZBQH-UHFFFAOYSA-N Methazole Chemical compound O=C1N(C)C(=O)ON1C1=CC=C(Cl)C(Cl)=C1 LRUUNMYPIBZBQH-UHFFFAOYSA-N 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101000969099 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Mating-type protein ALPHA1 Proteins 0.000 description 1
- 101001047925 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Silenced mating-type protein ALPHA1 Proteins 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- PDOCBJADCWMDGL-UHFFFAOYSA-N Sipatrigine Chemical compound C1CN(C)CCN1C1=NC=C(C=2C(=C(Cl)C=C(Cl)C=2)Cl)C(N)=N1 PDOCBJADCWMDGL-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 108010051181 TNK-tissue plasminogen activator Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000001065 Unilateral Hearing Loss Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000003180 beta-lactone group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003536 defibrinogenating effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- SRWAMKHZLDKAHZ-UHFFFAOYSA-L disodium;benzene-1,2-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC=CC=C1S([O-])(=O)=O SRWAMKHZLDKAHZ-UHFFFAOYSA-L 0.000 description 1
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
- 229950004794 dizocilpine Drugs 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229950005455 eliprodil Drugs 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- OZFSWVOEXHGDES-INIZCTEOSA-N lubeluzole Chemical compound C([C@@H](O)CN1CCC(CC1)N(C)C=1SC2=CC=CC=C2N=1)OC1=CC=C(F)C(F)=C1 OZFSWVOEXHGDES-INIZCTEOSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940075461 other therapeutic product in atc Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 108010085108 pamiteplase Proteins 0.000 description 1
- 229950003603 pamiteplase Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 210000003388 posterior cerebral artery Anatomy 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950009092 rovelizumab Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960002055 saruplase Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229950008911 sipatrigine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82386806P | 2006-08-29 | 2006-08-29 | |
| US60/823868 | 2006-08-29 | ||
| PCT/US2007/074997 WO2008027687A2 (en) | 2006-08-29 | 2007-08-01 | Use of tenecteplase for treating acute ischemic stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0716143A2 true BRPI0716143A2 (pt) | 2013-11-26 |
Family
ID=38835003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0716143-3A BRPI0716143A2 (pt) | 2006-08-29 | 2007-08-01 | Uso de tenecteplase para tratar derrame isquêmico agudo |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20080107641A1 (enExample) |
| EP (1) | EP2056856B1 (enExample) |
| JP (1) | JP5785687B2 (enExample) |
| KR (1) | KR20090045405A (enExample) |
| CN (1) | CN101505785A (enExample) |
| AU (1) | AU2007290277B2 (enExample) |
| BR (1) | BRPI0716143A2 (enExample) |
| CA (1) | CA2661012C (enExample) |
| CO (1) | CO6150188A2 (enExample) |
| EA (1) | EA015573B1 (enExample) |
| EC (1) | ECSP099178A (enExample) |
| IL (2) | IL196987A (enExample) |
| MX (1) | MX2009001918A (enExample) |
| MY (1) | MY163119A (enExample) |
| NO (1) | NO342302B1 (enExample) |
| NZ (1) | NZ574767A (enExample) |
| SG (3) | SG10201501498VA (enExample) |
| TW (1) | TWI439282B (enExample) |
| UA (1) | UA97486C2 (enExample) |
| WO (1) | WO2008027687A2 (enExample) |
| ZA (1) | ZA200900957B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
| US8030350B2 (en) | 2005-02-24 | 2011-10-04 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
| TWI439282B (zh) | 2006-08-29 | 2014-06-01 | Genentech Inc | 以血栓溶解劑治療中風之方法 |
| MX2009010988A (es) | 2007-04-13 | 2010-03-15 | Diffusion Pharmaceuticals Llc | Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica. |
| US9034007B2 (en) | 2007-09-21 | 2015-05-19 | Insera Therapeutics, Inc. | Distal embolic protection devices with a variable thickness microguidewire and methods for their use |
| JP2012513812A (ja) * | 2008-12-24 | 2012-06-21 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Ｍｒ卒中検出および処置による心臓介入のシステム、方法および装置 |
| EP2445339B1 (en) | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Diffusion enhancing compound and its use with a thrombolytic |
| JP5762414B2 (ja) * | 2009-08-24 | 2015-08-12 | ハフ イヤ インスティテュート | 急性音響外傷の治療方法 |
| ES2654945T3 (es) | 2010-06-02 | 2018-02-15 | Diffusion Pharmaceuticals Llc | Formulaciones orales de carotenoides trans bipolares |
| MY171723A (en) * | 2010-12-23 | 2019-10-24 | Gennova Biopharmaceuticals Ltd | Pharmaceutical compositions of tenecteplase |
| WO2014062888A1 (en) | 2012-10-18 | 2014-04-24 | University Of South Florida | Compositions and methods for treating stroke |
| US8715315B1 (en) | 2013-03-15 | 2014-05-06 | Insera Therapeutics, Inc. | Vascular treatment systems |
| US8679150B1 (en) | 2013-03-15 | 2014-03-25 | Insera Therapeutics, Inc. | Shape-set textile structure based mechanical thrombectomy methods |
| JP6437517B2 (ja) | 2013-03-15 | 2018-12-12 | インセラ セラピューティクス，インク． | 血管治療装置及び方法 |
| US8715314B1 (en) | 2013-03-15 | 2014-05-06 | Insera Therapeutics, Inc. | Vascular treatment measurement methods |
| US10220008B2 (en) | 2013-08-14 | 2019-03-05 | Stc.Unm | Treatment and prevention of stroke and other neurological disorders |
| MX383595B (es) * | 2014-10-21 | 2025-03-14 | Gennova Biopharmaceuticals Ltd | Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa) |
| CN108697423A (zh) | 2016-02-16 | 2018-10-23 | 伊瑟拉医疗公司 | 抽吸装置和锚定的分流装置 |
| WO2017165667A1 (en) | 2016-03-24 | 2017-09-28 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
| EP3573635B1 (en) * | 2017-01-24 | 2021-05-12 | Ekos Corporation | Method for the treatment of thromboembolism |
| EP3624832B1 (en) * | 2017-05-16 | 2025-08-20 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of acute ischemic stroke |
| US10426424B2 (en) | 2017-11-21 | 2019-10-01 | General Electric Company | System and method for generating and performing imaging protocol simulations |
| WO2021158799A1 (en) * | 2020-02-04 | 2021-08-12 | The Regents Of The University Of Colorado, A Body Corporate | Prophylactic uses of annexin a2 |
| MX2022010160A (es) * | 2020-02-19 | 2022-10-10 | Nono Inc | Tratamiento de combinación de apoplejia con inhibidor de psd-95 escindible por plasmina y reperfusión. |
| CN114984197A (zh) * | 2022-07-01 | 2022-09-02 | 江苏丰华生物制药有限公司 | 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用 |
| CN115487294A (zh) * | 2022-07-12 | 2022-12-20 | 上海丰华天力通生物医药有限公司 | 替奈普酶在制备用于治疗轻型缺血性卒中的药物组合物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0786257B1 (en) | 1992-06-03 | 2003-07-30 | Genentech, Inc. | Tissue plasminogen activator glycosylation variants with improved therapeutic properties |
| JP2002173447A (ja) * | 2000-09-29 | 2002-06-21 | Yamanouchi Pharmaceut Co Ltd | 脳塞栓症治療用医薬組成物 |
| US7084118B2 (en) * | 2002-02-22 | 2006-08-01 | Genentech, Inc. | Combination treatment with t-PA variant and low molecular weight heparin |
| US20030180282A1 (en) * | 2002-03-25 | 2003-09-25 | Victor Serebruany | Method of treatment of thrombotic events |
| US20070014779A1 (en) * | 2002-11-14 | 2007-01-18 | Genentech, Inc. | Plasminogen activator variant formulations |
| WO2006094120A2 (en) * | 2005-03-02 | 2006-09-08 | The Regents Of The University Of California | Treatment for embolic stroke |
| TWI439282B (zh) | 2006-08-29 | 2014-06-01 | Genentech Inc | 以血栓溶解劑治療中風之方法 |
-
2007
- 2007-08-01 TW TW096128284A patent/TWI439282B/zh active
- 2007-08-01 AU AU2007290277A patent/AU2007290277B2/en active Active
- 2007-08-01 ZA ZA200900957A patent/ZA200900957B/xx unknown
- 2007-08-01 WO PCT/US2007/074997 patent/WO2008027687A2/en not_active Ceased
- 2007-08-01 CA CA2661012A patent/CA2661012C/en not_active Expired - Fee Related
- 2007-08-01 MY MYPI20090793A patent/MY163119A/en unknown
- 2007-08-01 CN CNA2007800318116A patent/CN101505785A/zh active Pending
- 2007-08-01 EP EP07840638.6A patent/EP2056856B1/en active Active
- 2007-08-01 EA EA200970237A patent/EA015573B1/ru unknown
- 2007-08-01 JP JP2009526788A patent/JP5785687B2/ja active Active
- 2007-08-01 UA UAA200902855A patent/UA97486C2/ru unknown
- 2007-08-01 SG SG10201501498VA patent/SG10201501498VA/en unknown
- 2007-08-01 US US11/832,291 patent/US20080107641A1/en not_active Abandoned
- 2007-08-01 MX MX2009001918A patent/MX2009001918A/es active IP Right Grant
- 2007-08-01 NZ NZ574767A patent/NZ574767A/en unknown
- 2007-08-01 BR BRPI0716143-3A patent/BRPI0716143A2/pt not_active Application Discontinuation
- 2007-08-01 SG SG10201804944XA patent/SG10201804944XA/en unknown
- 2007-08-01 KR KR1020097006363A patent/KR20090045405A/ko not_active Ceased
- 2007-08-01 SG SG2011062213A patent/SG174753A1/en unknown
-
2009
- 2009-02-09 IL IL196987A patent/IL196987A/en active IP Right Grant
- 2009-02-27 CO CO09020350A patent/CO6150188A2/es unknown
- 2009-03-12 EC EC2009009178A patent/ECSP099178A/es unknown
- 2009-03-27 NO NO20091296A patent/NO342302B1/no unknown
-
2011
- 2011-07-22 US US13/189,413 patent/US9023346B2/en active Active
-
2016
- 2016-10-05 IL IL248176A patent/IL248176A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007290277B2 (en) | Use of tenecteplase for treating acute ischemic stroke | |
| EP2034830B1 (en) | Anti-vla-1 antibody for treating stroke | |
| Levine et al. | A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism | |
| EP3391901A1 (en) | Method for preventing or treating liver tissue damage and associated diseases | |
| US20230141921A1 (en) | Method and medicine for treating huntington's disease | |
| EP4245312A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| JP2022519327A (ja) | 頭蓋内出血の治療方法及び効果の評価方法 | |
| ES2772802T3 (es) | Composiciones y procedimientos para tratar la hemorragia intracerebral | |
| HK1131054B (en) | Use of tenecteplase for treating acute ischemic stroke | |
| Clark et al. | Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents | |
| JP2022551373A (ja) | 三環式誘導体を用いた脳卒中の治療方法 | |
| HK40099476A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40119109A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| Weiner | Thrombolytic agents in critical care | |
| KR20210014024A (ko) | 트리사이클릭 유도체를 이용한 뇌졸중의 치료 방법 | |
| FAST | What happens during a stroke | |
| Zhang et al. | Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice | |
| JP2008507561A (ja) | 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害 | |
| AHN et al. | Recombinant Factor VIIa Treatment for Acute Intracerebral Hemorrhage | |
| WO2007134813A2 (en) | Use of desmodus salivary plasminogen activator (dspa) for treating venous thromboembolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |